Figure 6

(A) FACS analyzed the Th17 cells surface markers CD4 and IL-17A expression in Peripheral blood from MOCK group. (B) FACS analyzed the Th17 cells surface markers CD4 and IL-17A expression in Peripheral blood from ITP group. (C) FACS analyzed the Th17 cells surface markers CD4 and IL-17A expression in Peripheral blood from AntagomiR641 group. (D) Statistic analysis of FACS results: CD4⁺IL17A⁺ Th17 cells were up-regulated in peripheral blood from ITP group (red column) comparing that from MOCK group (dark blue column) . Administration of AntagomiR 641 could down-regulate the CD4⁺IL17A⁺ Th17 cells (light blue column). (E) FACS analyzed the Treg cells surface markers CD25 and Foxp3 expression in Peripheral blood from MOCK group. (F) FACS analyzed the Treg cells surface markers CD25 and Foxp3 expression in Peripheral blood from ITP group. (G) FACS analyzed the Treg cells surface markers CD25 and Foxp3 expression in Peripheral blood from AntagomiR 641 group. (H) Statistic analysis of FACS results: CD25⁺Foxp3⁺ Treg cells were down-regulated in peripheral blood from ITP group (red column) comparing that from MOCK group (dark blue column) . Administration of AntagomiR 641 could restore the CD25⁺Foxp3⁺ Treg cells (light blue column). All FACS analysis underwent biological replication (n = 3).